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ABSTRACT  
Background & Aims: Fatigue is the commonest symptom described by patients in most populations 
with the autoimmune liver disease primary biliary cirrhosis (PBC), and appears to be unrelated to liver 
disease severity. At present it is unclear how the fatigue experienced by patients (only characterised to 
date in cross-sectional studies) evolves over time. In this study we set out to address how fatigue had 
changed over 4 years of follow-up in a geographically defined cohort of PBC patient who participated 
in an earlier cross-sectional study of fatigue impact. 
Methods: Participants in the original 2000 study who were still alive in 2004 were asked to complete 
the same fatigue assessment tool (FIS). In those who had died between 2000 and 2004 medical notes, 
death certificates and primary care records were reviewed. 
Results: 108 of the original cohort of 136 patients were alive at the time of the follow-up study, 99 of 
whom (92%) participated in the follow-up study. With the exception of 4 patients who underwent 
transplantation between 2000 and 2004, all of whom showed significant improvement in fatigue 
severity as assessed by FIS, fatigue severity was unchanged over 4 years of follow-up. Amongst the 
28 patients who died during the follow-up period survival was significantly lower in the patients who 
were fatigued at the 2000 baseline (FIS above the median for the whole PBC population (40/160)) 
(Log-Rank Test p=0.006 v non-fatigued at baseline patients). Increased fatigue severity was 
independently associated with decreased survival on multi-variate analysis.  Fatigued PBC subjects 
were significantly more likely to have suffered a cardiac death than non-fatigued patients. 
Conclusions: The fatigue phenotype appears to be highly stable in PBC. The presence of fatigue in 
PBC is independently associated with significantly increased risk of death in general and cardiac death 
in particular. The factors underpinning fatigue in PBC, and the mechanisms whereby fatigue is 
associated with increased mortality, warrant further study. 
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INTRODUCTION 
Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease with an autoimmune aetiology 
.[1][2] Studies performed in UK’[3][4] Canadian,[5][6] USA [7][8] and French [9] populations have 
suggested that the condition is frequently characterised by profound fatigue which can often 
dramatically reduce patient quality of life.[10] The severity of the fatigue experienced by UK PBC 
patients is significantly greater than that experienced by age- and sex-matched chronic disease and 
community controls. [3][4] A recent small study based on a principally Scandinavian cohort did not, 
in contrast, identify significant fatigue in PBC patients suggesting the possibility of population 
variation in symptom penetrance.[11] In contrast to PBC-associated pruritus, where significant recent 
progress has been made in understanding symptom pathogenesis and in optimising treatment,[12] 
PBC-associated fatigue remains largely resistant to treatment,[13] although this is an area of active 
ongoing investigation.[14][15] The limited studies performed to date in PBC and in animal models of 
cholestasis regarding fatigue pathogenesis have suggested a significant role for centrally-mediated 
processes. [16][17][18][19] Studies of the disease associations of fatigue in PBC have shown 
universal agreement that, in contrast to pruritus, the severity of fatigue experienced by PBC patients 
shows no relationship to any conventional parameter of liver disease severity, suggesting that fatigue 
may be less a direct result of liver pathology and more an independent manifestation of PBC as a 
systemic disease.[5][6][3] 
All studies addressing fatigue in PBC published to date have been cross-sectional in nature. It 
is, therefore, unclear how the impact of fatigue on individual patients changes over time. Indeed, it is 
not even clear whether the subgroup of patients experiencing fatigue (which ranges from 30 to 80% of 
all patients depending on the population studied and the quantification approach used) is static or 
whether all patients experience fatigue some of the time. Furthermore there is little information as to 
the relationship between the symptom of fatigue and prognosis.  The aim of this study was to address 
the question of how fatigue changes over time in PBC, and to study the effects on clinical outcome of 
high and low fatigue states by performing follow-up assessment of a representative group of PBC 
patients originally studied in 2000.[4] This group of patients constituted a comprehensive, unselected 
cohort of PBC patients defined by geography, and was identified specifically to allow us to study 
fatigue severity in a meaningful patient cohort not biased by clinic attendance frequency.  
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SUBJECTS AND METHODS 
The study cohort consisted of 136 patients defined by residence within the geographical area NE1-
NE25 (Newcastle-upon-Tyne and surrounding suburbs) who participated in a previous study of 
fatigue and its impact in PBC.[4] The median FIS for this population was 40 (maximum possible 
160). For the purposes of this follow-up study patients with an FIS ≥40 at the study outset were 
defined as the high fatigue group and FIS<40 the low fatigue group. The rationale for studying this 
patient population, and the methods used to identify the study population have previously been 
described.[4] At the time of initial study all patients were asked to complete a symptom assessment 
tool that determined self-perceived health status and also contained the Fatigue Impact Score (FIS), 
previously validated as a fatigue assessment tool for self-completion use in English speaking PBC 
patients.[3][6] Patients also completed a detailed questionnaire addressing any other health problems 
that they were experiencing, and the medications that they were receiving. Pruritus severity was 
assessed using a visual analogue scale (VAS).  For the follow-up study, patients were sent the same 
symptom and health assessment tool. Where patients had died comprehensive additional information 
regarding clinical events prior to death was gathered from hospital records, primary health care 
records and death certificates to supplement the study documentation. Using a previously adopted 
approach for cause of death assignation,[20] two of the investigators (JN and NB) examined all case 
documentation for each patient who died and independently ascribed the principal cause of death. 
Agreement regarding cause was present for all cases. The investigators who ascribed principal cause 
of death from the case documentation were blinded at the time as to the fatigue status at study 
enrolment of the patients who died. The design adopted for the control arm of the original cohort 
study, which included full anonymisation of controls subjects, precluded us from performing a follow-
up study of the control subjects. Ethical approval for this study was granted by the local research 
ethics committee. 
Statistical Analysis 
Survival following the original cohort study was compared in fatigued and non-fatigued patients using 
the Log-Rank Test. Proportions of fatigued and non-fatigued patients suffering cardiac death were 
compared using Fishers Exact Test. Cox proportional hazards regression was performed using SPSS 
to assess whether any association between fatigue scores and survival was independent of other 
clinical variables. Comparisons of biological parameters at enrolment between fatigued and non-
fatigued patients who subsequently died on follow-up, and of FIS values at enrolment and follow-up 
were by parametric and non-parametric t-test as appropriate for the nature of the population value 
distributions. Proportions of patients in relevant subgroups were compared using Fishers Exact Test.     
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RESULTS 
Study Cohort 
Of the original cohort of 136 patients 28 (21%) died between the initial and follow-up assessments. 
Detailed clinical records were available for all these patients. Of the 108 survivors from the original 
cohort 99 (92%) participated in the follow-up study. Patient demographic clinical and laboratory data 
are given in Table 1. Four of the surviving patients and none of the non-survivors had undergone liver 
transplantation between initial assessment and follow-up.  
 
Table 1: Demographic data for patients at the study outset. [4] Amongst the patients from the original 
cohort who were alive at follow-up (n=108) data are only given for those who agreed to participate in 
the follow-up element of the study (n=99, 92%). Unless otherwise indicated data are presented as 
median and [range]. na denotes not applicable 
  
Baseline Variable All Patients Patients Alive at 
Follow-Up 
Patients Dead at 
Follow-Up 
Age (years) 65 [21-88] 62 [21-88] 77 [53-86] 
Bilirubin (µmol/l) 8 [3-131] 8 [3-131] 10 [4-69] 
Albumin (g/l) 42 [28-51] 42 [28-51] 40 [35.5-45] 
Prothrombin Time (s) 13 [11-24] 13 [11-24] 13 [12-18] 
UDCA Therapy 
(number [%]) 
39 [31] 28 [28] 11 [39] 
Definite Disease 
(number [%]) 
81 [64] 62 [63] 19 [68] 
Probable Disease 
(number [%]) 
46 [36] 37 [37] 9 [32] 
Histologically 
Confirmed Advanced 
Disease 
(number [%]) 
14 [11] 9 [9] 5 [18] 
Pruritus Present at 
Enrolment 
(number [%] 
84 [62] 64 [59] 20 [71] 
FIS at Enrolment 40.5 [0-138] 35.5 [0-136] 54.5 [2-138] 
FIS at FU na 37.5 [0-142] na 
Female 
(number [%]) 
116 [91] 90 [91] 26 [93] 
 
Subjects Surviving to Follow-Up 
Amongst the 95 surviving, non-transplanted patients fatigue severity as assessed by the FIS was 
unchanged after the 4 year follow-up period (Fig 1a & b). Significant change in fatigue score status 
amongst individual patients over the follow-up period was limited to the four patients who underwent 
transplantation, all of whom reported significant improvements in their FIS score (Fig 1b & c). 
Ursodeoxycholic acid (UDCA) usage appeared to have no detectable effect on fatigue severity (within 
the constraints of the study methodology) as no significant change in FIS was seen between 2000 and 
2004 in patients not receiving UDCA at any point during the study period (Fig 2a), in patients who 
commenced UDCA at standard doses (12-15g/Kg/day) between 2000 and 2004 (Fig 2b) and in 
patients receiving UDCA throughout the study period (Fig 2c).  
 
Subjects Not Surviving to Follow-Up 
The patients who died during follow-up had higher FIS values at the study outset (median FIS 54.5  
[range 2-138]) than the patients who survived to follow-up and who participated in the follow-up arm 
of the study (median FIS 35.5 [0-136], p<0.05, Fig 3a). 20/28 (71%) of the patients dying during 
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follow-up had high fatigue scores at study outset (defined as FIS values above the median value for 
the whole PBC population (>40)) compared with 8/28 (29%) with low fatigue scores (defined as FIS 
values of FIS<40), p<0.005. By contrast, proportions of surviving and non-surviving patients with 
pruritus at the study outset (VAS >0) were similar (Table 1, p=ns). Survival over the study follow-up 
period was significantly lower by Kaplan-Meier analysis for the high fatigue patients at the study 
outset than for the low fatigue patients (Fig 3b). Presence of pruritus was, in contrast, not associated 
with significantly decreased survival by Kaplan-Meier analysis (data not shown). The association 
between a high fatigue score (FIS>40) at the study outset and risk of mortality on follow-up was 
independent of other, well established PBC prognosis associated variables (age, bilirubin and albumin 
which were found, along with FIS, to be associated with prognosis in this cohort on univariate 
analysis (data not shown)) and on Cox proportional hazard regression analysis (Table 2).    
 
Table 2: Baseline biological parameters showing significant associations with subsequent survival on 
proportional hazards regression. 
 
Variable B SE(B) P 
FIS 0.91 0.43 0.03 
Age 0.095 0.023 <0.001 
Albumin -0.095 0.045 0.04 
Bilirubin 0.027 0.01 0.01 
 
 
No association was seen between age or any parameter of liver disease severity (including serum 
albumin, bilirubin and PT) and fatigue severity in the whole study cohort at enrolment.[4] This 
observation remained true in retrospect for the group who went on to die during follow-up (Table 3). 
Moreover, the vast majority of patients in both the fatigued and non-fatigued groups at study outset 
who died during follow-up had normal liver synthetic function (Table 3). In terms of more general 
parameters of health, no correlation was also seen between self-reported general health status (which 
patients were asked to distinguish from fatigue), numbers of medications received blood glucose and 
TSH levels and fatigue severity at the study outset in the subjects who died during follow-up (Table 
3).  
 
Table 3: Baseline biological parameters and frequencies of abnormal values for key parameters and 
fatigue associated diagnoses in patients with high (FIS >40) and low (FIS<40) fatigue scores at study 
enrolment who died during follow-up. Health perception scores was a self-reported score of general 
health with values ranging from 1 (very poor health) to 4 (very good health). Subjects completing this 
scale were asked to consider the aspects of their health other than their fatigue. Number of 
medications received relates to prescription medications.  
 
Variable FIS>40 
n=20 
FIS<40 
n=8 
P 
Albumin (g/l) 
(n [%] albumin <35g/l)  
40 [36-45] 
(0 [0]) 
38 [35.5-42] 
(0 [0]) 
ns 
(ns) 
Bilirubin (µmol/l) 
(n [%] bilirubin >17µmol/l) 
12 [4-69] 
(3 [15]) 
10 [8-47] 
(1 [12.5]) 
ns 
(ns) 
PT (seconds) 
(n [%] PT >15sec) 
13 [12-15] 
(0 [0]) 
13 [12-18] 
(2 [25]) 
ns 
(ns) 
TSH (mu/l) 
(n [%] diagnosed thyroid disease) 
2.3 [0.5-3.8] 
(1 [5]) 
1.7 [1.2-2.8] 
(1 [12.5]) 
ns 
(ns) 
Random Blood Glucose (mmol/l) 
(n [%] diagnosed Type II DM) 
7.0 [4.4-9.0] 
(2 [10]) 
8.0 [4.4-9.1] 
(0 [0]) 
ns 
(ns) 
Age (years) 75 [54-86] 71 [53-86] Ns 
Health Perception Score (1-4) 2 [1-4] 2 [1-3] Ns 
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Numbers of Medications Received 2 [0-5] 2 [0-6] Ns 
 
Despite the independent association between both albumin and bilirubin at enrolment and subsequent 
survival, liver disease was attributed as a direct cause of death in only 4 patients (variceal bleed n=2 & 
liver failure in 2). In contrast, 9 died of histologically confirmed malignant disease (carcinoma of the 
bronchus (n=3), oesophagus (n=2), breast (n=1) colon (n=1) and pancreas (n=1) and non-Hodgkin’s 
lymphoma (n=1). Of the remaining 15 patients 2 died of respiratory system sepsis not directly linked 
to liver disease (ie not following endoscopic procedures) and 13 were ascribed a cardiac cause of 
death (sudden cardiac events occurring in the absence of previous symptoms (all investigated with 
post-mortem) n=5, myocardial infarction n=5 and heart failure n=3). A principally cardiac cause of 
death was seen significantly more frequently seen in the group of patients with high outset fatigue 
scores who died during follow-up (12/20, 60%) than in the group of patients with low outset fatigue 
scores who died during follow-up (1/8, 12.5%, p<0.05).  
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DISCUSSION 
In this study we set out to explore how the impact of fatigue evolves over time in PBC. The study 
population was a well-characterised and representative cohort of patients, defined by geography of 
residence, who had participated in an earlier study of fatigue impact in PBC.[4] The follow-up 
assessment reported in the current study took place 4 years after the original assessment. Full follow-
up information was available for 93% of the original study cohort (99 subjects who were alive and 
participated in the follow-up study and 28 who had died during the follow-up period).  
Fatigue severity as determined by FIS was unchanged in 2000 compared to 2004 amongst the 
patients not undergoing liver transplantation during follow-up. One potential explanation for this 
finding would be that the FIS lacks the responsiveness [21] to detect change in fatigue severity over 
time. The observations that the FIS had sufficient responsiveness to detect statistically significant 
improvement in fatigue severity in the small number of patients who did undergo liver transplantation 
in the follow-up phase of this study, and that the FIS has been demonstrated to be able to detect 
significant changes in fatigue severity in response to therapy in other disease settings,[22][23] would 
argue against this interpretation. The alternative explanation for the stability of the FIS over time, and 
the one which we favour, is that little or no change in fatigue severity in fact occurred over the time-
period of the study. The conventional view to date in PBC has been that the condition goes through an 
initial asymptomatic phase which is followed by symptom development and, in due course, by the 
development of progressive disease.[24][25][26][27][28] If our interpretation is correct our 
observations would challenge this view. The findings of the current study suggest that patients fall 
into fatigued and non-fatigued groups which, at least over 4 years, remain stable. Moreover, the use of 
UDCA, an agent demonstrated to slow the progression of liver disease and improve liver biochemistry 
in PBC,[29] appears to have no identifiable effect on fatigue severity. These observations would be 
more supportive of fatigue in PBC resulting from pathological processes to which PBC in some way 
acts as a co-factor, and to which PBC patients are thus pre-disposed, than it occurring as a direct 
consequence of liver disease.   
The mortality rate for patients who participated in the original fatigue study cohort was 20.6%. 
Death certificate data were available for all the patients who died during follow-up allowing 
confirmation of the mortality rate. The annualised mortality rate observed for the current cohort was 
very similar to that reported by our group for an earlier cohort of North-Eastern UK PBC patients. 
[20] The apparent differences in mortality rates between the two Newcastle studies and a recent 
French study [30] are likely to reflect different patient demographics. Survival was significantly lower 
in patients with high fatigue scores at the study outset, with high FIS being independently associated 
with reduced survival on multi-variate analysis (the B  value on proportional hazards regression for 
FIS>40 at study outset was 0.91 (p<0.05) indicating that presence of fatigue at the study outset 
(defined as FIS>40) was independently associated with a relative risk of dying during follow-up of 
1.91 compared to the risk in patients in whom fatigue was absent (defined as FIS<40)). The other 
adverse prognostic indicators at enrolment for the current cohort were age, serum albumin and serum 
bilirubin (parameters previously well established as markers of adverse prognosis in PBC).  These 
observations suggest that the pathological processes responsible for fatigue expression in PBC are not 
benign.  
In this study cohort cardiac, but not malignant, or directly liver disease-associated deaths were 
significantly over-represented in the subgroup of patients who had high fatigue severity scores at the 
outset of the study. There are several potential explanations for the apparent association between 
fatigue and subsequent cardiac death. The first would be incorrect mode of death assignment. We 
could find no evidence to support this possibility. Indeed, all cardiac death patients had positive 
diagnostic findings (ECG features of arrhythmia or myocardial infarction or echo-cardiographic 
features of heart failure) or post-mortem findings compatible with cardiac cause of death. The 
difficulties inherent in cause of death assignment particularly in the context of sudden cardiac death 
secondary to arrhythmia even following post-mortem mean, however, that the possibility of error in 
cause of death assignment remain. A second potential explanation would be that the high fatigue 
group at the outset of study contained a proportion of patients with pre-existing atherosclerotic 
cardiovascular disease or heart failure, or risk factors for the development of such disease (such as 
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diabetes), which pre-disposed to both their fatigue at the time of the study and their subsequent death. 
The limitations of the original study protocol mean, however, that although the available records 
confirm that diagnosed heart disease and risk factors for heart disease were absent from the vast 
majority of the patients who subsequently died of cardiac causes we cannot exclude the possibility 
that occult heart disease was present in a number of the fatigued patients who died of cardiac causes 
during follow-up. If this were the case (and future prospective studies addressing cardiac risk together 
with fatigue assessment in PBC will be required to answer this question) it would have implications 
for our understanding of fatigue pathogenesis in PBC (implying, as it does, multi-factorial aetiology 
with the implication that a single agent approach to therapy is less likely to be effective) and would 
add to the ongoing debate regarding atherosclerotic disease risk in PBC.[31][32]       
A third explanation for the apparent links between fatigue in PBC and cardiovascular mortality 
might be autonomic dysfunction. Our group, and others, have recently identified a high prevalence of 
abnormalities of autonomic function in PBC patients (including reduced heart-rate variability and 
blood-pressure instability.[33][34][35][36] Autonomic dysfunction of this type has previously been 
demonstrated (in the non-liver setting) to be associated with an increased risk of cardiac mortality 
(including sudden cardiac death).[37][38][39] Furthermore, degree of autonomic dysfunction has 
previously been demonstrated to show an association with fatigue severity in both PBC [35] and other 
fatigue associated conditions such as multiple sclerosis,[40] autonomic failure [41] and chronic 
fatigue syndrome.[42][43][44] One explanation for our findings might therefore be that PBC 
predisposes to autonomic dysfunction which results in fatigue, but which also puts affected patients at 
risk of cardiac death via mechanisms (such as sudden cardiac death) which may have been under-
detected in earlier studies of cardiac risk in PBC which typically focused on atherosclerotic disease.  
In this study we have demonstrated that, in PBC patients affected by fatigue (and not all 
patients and populations are so affected) the symptom is a chronic one with, seemingly, little evidence 
of spontaneous or therapy-related resolution. This symptom constancy, together with the emerging 
evidence regarding the degree to which it can impair quality of life, means that further efforts to 
identify therapies able to ameliorate fatigue in PBC are warranted. Our observations regarding the 
apparent associations between fatigue, reduced survival, and apparent risk of cardiac-related death add 
further complexity of our current understanding of the pathogenesis of fatigue in PBC. Further 
prospective studies in this area are again warranted.    
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Figure 1: a) Distribution of FIS values in 2000 and 2004 in patients surviving to follow-up who were 
not transplanted during the follow-up period. Mean value is denoted. b) Correlation between 
individual FIS values in patients in 2000 and 2004. Non-transplanted patients are denoted by closed 
circles, patients transplanted during follow-up by open circles. Correlation data (with 95% CI) are  for 
the non-transplanted patient group. c) Distribution of FIS values in 2000 and 2004 in patients 
surviving to follow-up who were transplanted during the follow-up period. Mean value is denoted.   
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Figure 2: FIS values in 2000 and 2004 for a) Patients not receiving UDCA at any stage of the study. 
b) Patients who commenced UDCA at a dose of 10-12mg/Kg between 2000 and 2004 and who were 
still receiving this medication at the time of the follow-up study. c) Patients receiving UDCA at a dose 
of 10-12mg/Kg throughout the study period.  
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Figure 3: a) Comparison of the FIS values at the study outset for patients who survived to follow-up 
and in those who died during follow-up (horizontal bar denoted median value). b) Survival in patients 
in the 2000 study cohort with fatigue scores above and below 40 (the median score for PBC patients 
in this cohort).[4] 
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